Xilio Therapeutics, Inc. (XLO) Financials
XLO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 163.5 million | 90.9 million |
| Dec. 31, 2025 | 154.7 million | 119.4 million |
| Sept. 30, 2025 | 133.7 million | 141.8 million |
| June 30, 2025 | 133.8 million | 126.7 million |
XLO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -22.9 million | ? |
| Dec. 31, 2025 | -2.1 million | 2.9 million |
| Sept. 30, 2025 | -17.5 million | 1.1 million |
| June 30, 2025 | -14.9 million | 1.4 million |
XLO Net Income
No data available :(
XLO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 150.3 million | 5.3 million | - |
| Dec. 31, 2025 | 137.5 million | 5.6 million | 7.0 million |
| Sept. 30, 2025 | 103.8 million | 6.0 million | 7.3 million |
| June 30, 2025 | 121.6 million | - | 7.6 million |
XLO Shares Outstanding
XLO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 556000 | 19.8 million | 6.6 million | -344000 |
| Dec. 31, 2025 | 95000 | 18.1 million | 7.4 million | - |
| Sept. 30, 2025 | - | 14.3 million | 6.7 million | - |
| June 30, 2025 | 401000 | 15.3 million | 7.1 million | - |
XLO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 12.6 million | 344000 |
| Dec. 31, 2025 | 13.7 million | 323000 |
| Sept. 30, 2025 | 19.1 million | 340000 |
| June 30, 2025 | 8.1 million | 15.3 million |
XLO
Price: $8.79
52 week price:
Earnings Per Share: -2.28 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 18100
Market Capitalization: 46.1 million